• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion Pharmaceuticals

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

December 28, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba. CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novo Nordisk, Sanofi-Aventis

Actelion, J&J re-enter takeover negotations

December 21, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotations

Actelion (VTX:ATLN) and Johnson & Johnson (NYSE:JNJ) have re-entered talks to reach a takeover deal, after the US healthcare giant reportedly abandoned its efforts last week. Some suggest that this could mean the end of Sanofi‘s (NYSE:SNY) attempt to make a deal with the Swiss biotech firm, according to Reuters.  J&J and Actelion had been engaged in informal talks […]

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Actelion gains on Sanofi deal rumors

December 16, 2016 By Sarah Faulkner

Actelion gains on Sanofi deal rumors

Actelion (VTX:ATLN) shares jumped more than 8% to 214 Swiss francs after reports that Sanofi (NYSE:SNY) and the Swiss biotech are nearing a takeover deal that would value Actelion at $29.6 billion. After Johnson & Johnson (NYSE:JNJ) abandoned its efforts to reach an agreement with Actelion this week, Sanofi stepped in to pursue negotiations. Sanofi is expected to offer […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Actelion, Sanofi in talks after J&J backs out of negotiations

December 14, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotations

Actelion (VTX:ATLN) and Sanofi (NYSE:SNY) are reportedly in talks to reach a takeover deal after Johnson & Johnson (NYSE:JNJ) said yesterday that it has closed negotiations with the Swiss biotech. J&J and Actelion have been in informal talks for nearly 2 months and the US company has made an offer valued at 250 Swiss francs per share. J&J said yesterday […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Sanofi throws hat in the ring with J&J’s in Actelion pursuit

December 6, 2016 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Pfizer Inc., Roche, Sanofi-Aventis

Hedge funds betting on J&J after Actelion remains silent on takeover bid

December 2, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Despite reports this week that Actelion Pharmaceuticals (VTX:ATLN) rejected Johnson & Johson‘s (NYSE:JNJ) 2nd takeover bid, hedge funds are piling into the Swiss biotech firm, encouraged by Actelion’s silence on the matter. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Actelion rejects J&J’s takeover offer

December 1, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN) reportedly rejected Johnson & Johnson‘s (NYSE:JNJ) 2nd takeover offer, sending it shares down -6% in afternoon trading yesterday. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. J&J’s $270 billion bid for Actelion tempted shareholders, […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Report: J&J raises the stakes in Actelion pursuit

November 30, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has reportedly raised its offer for Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN), pressuring the company to accept a takeover deal. The companies have been in talks for nearly 2 months but so far have not reached a deal, according to Reuters. The news outlet reported that Actelion wants J&J to become a major shareholder […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Roche

J&J approaches Actelion

November 28, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through. J&J’s CEO Alex Gorsky said this year that the company is interested in deals […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Roche, Sanofi-Aventis

  • « Go to Previous Page
  • Page 1
  • Page 2

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS